DIARYL-SUBSTITUTED 6,5-CONJUGED CYCLIC COMPOUNDS AS C5aR INHIBITORS Russian patent published in 2023 - IPC C07D231/56 C07D471/04 A61K31/437 A61K31/444 A61P29/00 A61P35/00 A61P37/00 A61P9/00 

FIELD: organic chemistry.

SUBSTANCE: invention relates to a heterocyclic compound of formula (I) or a pharmaceutically acceptable salt thereof, where cycle member a is C(R^2c), cycle member b is N or C(R^2d) and cycle member e is N or C(R^2e), where not more than one of b and e is N; X¹ is selected from the group consisting of bond, C_1-8 alkylene, C(O), C(O)-C_1-4 alkylene and S(O)₂; R¹ is selected from the group consisting of the following: a) 5–9 membered heteroaryl containing as ring vertices 1–3 heteroatoms selected from N and S; b) C_6-10 aryl; c) C_3-8 cycloalkyl; d) 4–8-membered heterocycloalkyl containing as ring vertex 1 a heteroatom selected from O; and e) C_1-8 alkyl, C_1-8 alkoxy, C_1-8 haloalkyl, and -C(O)NR^1aR^1b, wherein R^1a and R^1b are each independently selected from the group consisting of hydrogen and C_{1 -8} alkyl; where the group -X¹R¹ is optionally substituted with 1–5 substituents R^x; R^2a and R^2e are each independently selected from the group consisting of hydrogen, C_1-6 alkyl, C_1-6 alkoxy, C_1-6 haloalkyl, -O-C_1-6 haloalkyl, and halogen, and at least one of R^2a and R^2e is different from a hydrogen atom; R^2b, R^2c and R^2d are each independently selected from the group consisting of hydrogen and C_1-6 alkyl; each R³ is C_1-4 alkyl; R⁴ is independently selected from the group consisting of -X²-OR^4a, -X²NR^4aR^4b, -X²CONR^4aR^4b, -X²NR^4a-C(O)R^4a, -X²NR^4a-C(O)NR^4aR^4b, -X²NR^4a-C(O)-C_1-3 alkylene-OR^4a and -X²NR^4a-C(O)-C_1-3 alkylene-NR^4aR^4b where each X² is independently a bond and C_1-4 alkylene and each R^4a and R^4b is independently selected from the group consisting of hydrogen and C_1-4 alkyl; each R⁵ is independently selected from the group consisting of C_1-8 alkyl, C_1-8 alkoxy, halogen and CN; each R^x is independently selected from the group consisting of halo, CN, C_1-4 alkyl, C_1-4 alkoxy, C_1-4 haloalkyl, C_1-4 haloalkoxy, C_1-4 hydroxyalkyl, C_2-4 alkenyl, C_3-6 cycloalkyl, CO₂-C_1-4 alkyl and CONH₂; m and n are either 0, 1, or 2. The invention also relates to a pharmaceutical composition based on a compound of formula (I) and a method for treating a disease with a compound of formula (I) or a pharmaceutical composition based on it.

EFFECT: invention provides effective treatment of a disease associated with pathological activation of C5a receptors.

38 cl, 1 tbl, 13 ex